Pharmacokinetics and pharmacodynamics integration of danofloxacin against Eschrichia coli in piglet ileum ultrafiltration probe model

被引:0
|
作者
Yuqi Yang
Ping Cheng
Tianshi Xiao
Jargalsaikhan Ulziikhutag
Hongxiao Yu
Jiarui Li
Ruimeng Liu
Ishfaq Muhammad
Xiuying Zhang
机构
[1] University Town,Pharmacology Teaching and Research Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine
[2] Northeast Agricultural University,Heilongjiang Key Laboratory for Animal Disease Control and Pharmaceutical Development, Faculty of Basic Veterinary Science, College of Veterinary Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Improper use of antibiotics results in poor treatment and severe bacterial resistance. In this study, ultrafiltration probes were successfully placed in the ileum of piglets with the aid of anesthetic. After the fluoroquinolone antimicrobial drug danofloxacin (DAN) was intramuscularly administered, blood and ileum ultrafiltrate were collected at different time points and then determined by High Performance Liquid Chromatography (HPLC). Pharmacokinetics (PK) parameters for plasma and ileum ultrafiltrate were calculated by WinNonlin software. The DAN concentration in ileum ultrafiltrate was much higher than that in plasma during the period 1.2–48 h. The DAN concentration in plasma reached its maximum at 1.10 ± 0.03 h, but reached at 6.00 ± 0.00 h in the ileum ultrafiltrate. The mean Cmax of the ileum is 13.59 times that of plasma. The elimination half-life (T1/2β) in the ileum ultrafiltrate (6.84 ± 1.49 h) was shorter than those in plasma (7.58 ± 3.20 h). The MIC, MBC and MPC of DAN in MH broth against Escherichia coli (O158) were 0.5 µg/mL, 0.5 µg/mL and 4 µg/mL, respectively. Both in vitro and ex vivo kill curves indicated that the killing mechanism of DAN against E. coli is concentration-dependent. The AUC/MPC ratio is 21.33 ± 2.14. Mean PK/PD index (AUC24h/MIC) for ileum ultrafiltrate that achieved bacteriostatic, bactericidal, and eradication were 99.85, 155.57, and 218.02 h, respectively. Three different dosages (1.49 mg/kg, 2.42 mg/kg, and 3.24 mg/kg) were calculated respectively based on AUC24h/MIC ratio above, which might provide a novel approach to the rational design of dosage schedules.
引用
收藏
相关论文
共 50 条
  • [21] Ex vivo pharmacodynamics of amoxicillin-clavulanate against β-lactamase-producing Eschetichia coli in a Yucatan miniature pig model that mimics human pharmacokinetics
    Bronner, S
    Murbach, V
    Peter, JD
    Levêque, D
    Elkhaïli, H
    Salmon, Y
    Dhoyen, N
    Monteil, H
    Woodnutt, G
    Jehl, F
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) : 3782 - 3789
  • [22] Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice
    Jakobsen, Lotte
    Lundberg, Carina Vingsbro
    Frimodt-Moller, Niels
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (01)
  • [23] In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
    Lepak, Alexander J.
    Zhao, Miao
    VanScoy, Brian
    Taylor, Daniel S.
    Ellis-Grosse, Evelyn
    Ambrose, Paul G.
    Andes, David R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (06)
  • [24] Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model
    Sho Tashiro
    Marina Hayashi
    Wataru Takemura
    Yuki Igarashi
    Xiaoxi Liu
    Yuki Mizukami
    Nana Kojima
    Yuki Enoki
    Kazuaki Taguchi
    Yuta Yokoyama
    Tomonori Nakamura
    Kazuaki Matsumoto
    Pharmaceutical Research, 2021, 38 : 27 - 35
  • [25] Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model
    Tashiro, Sho
    Hayashi, Marina
    Takemura, Wataru
    Igarashi, Yuki
    Liu, Xiaoxi
    Mizukami, Yuki
    Kojima, Nana
    Enoki, Yuki
    Taguchi, Kazuaki
    Yokoyama, Yuta
    Nakamura, Tomonori
    Matsumoto, Kazuaki
    PHARMACEUTICAL RESEARCH, 2021, 38 (01) : 27 - 35
  • [26] Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX Against Staphylococcus aureus-Induced Mouse Peritonitis Model
    Zheng, Xueling
    Yang, Na
    Mao, Ruoyu
    Hao, Ya
    Teng, Da
    Wang, Jianhua
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [27] Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations
    Soon, Rachel L.
    Lenhard, Justin R.
    Bulman, Zackery P.
    Holden, Patricia N.
    Kelchlin, Pamela
    Steenbergen, Judith N.
    Friedrich, Lawrence V.
    Forrest, Alan
    Tsuji, Brian T.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (04) : 1967 - 1973
  • [28] In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model
    Zhang, Bingxu
    Gu, Xiaoyan
    Li, Yafei
    Li, Xiaohong
    Gu, Mengxiao
    Zhang, Nan
    Shen, Xiangguang
    Ding, Huanzhong
    BMC VETERINARY RESEARCH, 2014, 10
  • [29] Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model
    Singh, Sanjay
    Gumbo, Tawanda
    Boorgula, Gunavanthi D.
    Thomas, Tania A.
    Philley, Julie V.
    Srivastava, Shashikant
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (02)
  • [30] Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model
    Guo, Siwei
    Li, Xin
    Li, You
    Tong, Huan
    Wei, Minji
    Yan, Bingqian
    Tian, Miaomei
    Xu, Bing
    Shao, Jing
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (01) : 141 - 149